Why Catalyst Pharmaceutical Partners (CPRX) Stock Is Spiking Today

NEW YORK (TheStreet) -- Catalyst Pharmaceutical Partners  (CPRX) shares are up 14.2% to $3.41 on Tuesday after ROTH Capital raised the company's price target to $6 from $5 and reiterated its "buy" rating.

The upgraded outlook stems from Catalyst's positive phase III study results of Firdapse, a treatment for Lamber-Eaton Myasthenic Syndrome.

Some analysts believe that this news will lead to a prohibitive price tag of between $60,000 and $80,000 a year for the treatment.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet's Adam Feuerstein discusses the implications of the study results in depth here.

CPRX Chart CPRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists